The use of antifibrinolytic drugs in paediatric cardiac surgery

Paediatric and Perinatal Drug Therapy

Volumn 6, Issue 1, 2004, Pages 4-13

  Anderson, Brian J ^a,c   Morton, Graham ^a   McKenzie, Ian ^b  

^a GREEN LANE HOSPITAL   (New Zealand)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c STARSHIP CHILDREN S HOSPITAL   (New Zealand)

Author keywords

Antifibrinolysis; Cardiac surgery; Paediatric

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; TRANEXAMIC ACID;

ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONGENITAL HEART DISEASE; COST BENEFIT ANALYSIS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG URINE LEVEL; DRUG USE; FIBRINOLYSIS; HEART SURGERY; HUMAN; HYPERCOAGULABILITY; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY FAILURE; LUNG EMBOLISM; MEDIATOR RELEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PEDIATRIC SURGERY; PHARMACODYNAMICS; PROPHYLAXIS; RETINA ARTERY OCCLUSION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 4243096169     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: 10.1185/146300904125004146     Document Type: Review

References (58)

1. Manno CS, Hedberg KW, Kim HC et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991;77:930-936.
2. Edmunds LH, Jr. Invited letter concerning: aprotinin use in pediatric cardiac operations. J Thorac Cardiovasc Surg 1993;105:757-760.
3. Mossinger H, Dietrich W, Braun SL et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003;75:430-437.
4. Dowd NP, Karski JM, Cheng DC et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002;97:390-399.
5. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-261.
6. Fiechtner BK, Nuttall GA, Johnson ME et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001;92: 1131-1136.
7. Miller BE, Mochizuki T, Levy JH et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997;85:1196-1202.
8. Andrew M, Paes B, Milner R et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-172.
9. Yang YM, Simon N, Maertens P, Brigham S, Liu P. Maternal-fetal transport of vitamin K1 and its effects on coagulation in premature infants. J Pediatr 1989;115:1009-1013.
10. Boldt J, Knothe C, Zickmann B et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993;55:1460-1466.
11. Gross S, Keefer V, Liebman J. The platelets in cyanotic congenital heart disease. Pediatrics 1968;42:651-658.
12. Mauer HM, McCue CM, Caul J, Still WJ. Impairment in platelet aggregation in congenital heart disease. Blood 1972;40:207-216.
13. Komp DM, Sparrow AW. Polycythemia in cyanotic heart disease - a study of altered coagulation. J Pediatr 1970;76:231-236.
14. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986;67:758-761.
15. Miller BE, Bailey JM, Mancuso TJ et al. Functional maturity of the coagulation system in children: an evaluation using thrombelastography. Anesth Analg 1997;84:745-748.
16. Dietrich W, Mossinger H, Spannagl M et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-720.
17. Kirklin JK, Westaby S, Blackstone EH et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-857.
18. van Oeveren W, Kazatchkine MD, Descamps-Latscha B et al. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985;89: 888-899.
19. Edmunds LH, Jr. Blood-surface interactions during cardiopulmonary bypass. J Card Surg 1993;8: 404-410.
20. Greeley WJ, Bushman GA, Kong DL, Oldham HN, Peterson MB. Effects of cardiopulmonary bypass on eicosanoid metabolism during pediatric cardiovascular surgery. J Thorac Cardiovasc Surg 1988;95:842-849.
21. Kern FH, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992; 54:541-546.
22. Boldt J, Knothe C, Zickmann B et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993;105:705-711.
23. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93:229-237.
24. Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci 1968;146:642-658.
25. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991;38:113-119.
26. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992;69:307-313.
27. Grant HW, Hadley GP. Prediction of neonatal sepsis by thromboelastography. Pediatr Surg Int 1997; 12:289-292.
28. Goobie SM, Soriano SG, Zurakowski D, McGowan FX, Rockoff MA. Hemostatic changes in pediatric neurosurgical patients as evaluated by thrombelastograph. Anesth Analg 2001;93:887-892.
29. Martin P, Horkay F, Rajah SM, Walker DR. Monitoring of coagulation status using thrombelastography during paediatric open heart surgery. Int J Clin Monit Comput 1991;8:183-187.
30. Mannucci PM. Hemostatic drugs. NEJM 1998;339:245-253.
31. Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin 1995;33:155-179.
32. Reid RW, Zimmerman AA, Laussen PC et al. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg 1997;84:990-996.
33. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995;82:383-392.
34. Zonis Z, Seear M, Reichert C, Sett S, Allen C. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1996;111:982-987.
35. Bergstein JM. Introduction to glomerular diseases. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. Philadelphia: W.B. Saunders Co, 2000:1574-1575.
36. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Efficacy of epsilon-aminocaproic acid in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1999;13:304-308.
37. Chauhan S, Kumar BA, Rao BH et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg 2000;70:1308-1312.
38. Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998;66:153-158.
39. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;110:1658-1662.
40. Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354: 1940-1947.
41. Primack C, Walenga JM, Koza MJ, Shankey TV, Pifarre R. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg 1996;61:1188-1193.
42. Herynkopf F, Lucchese F, Pereira E et al. Aprotinin in children undergoing correction of congenital heart defects. A double-blind pilot study. J Thorac Cardiovasc Surg 1994;108:517-521.
43. Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg 1998;65:S45-50; discussion S50-1, S74-6.
44. Dietrich W, Spannagl M, Jochum M et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-1126.
45. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983;33:479-494.
46. Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg 2001;92:830-836.
47. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass - effects on the Hageman factor (FXII) - Kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992;3:99-104.
48. Nuttall GA, Fass DN, Oyen LJ, Oliver WC, Jr., Ereth MH. A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. Anesth Analg 2002;94:283-289.
49. Rustom R, Grime JS, Maltby P et al. Observations on the early renal uptake and later tubular metabolism of radiolabelled aprotinin (Trasylol) in man: theoretical and practical considerations. Clin Sci (Lond) 1993;84:231-235.
50. Bianchi C, Donadio C, Tramonti G et al. 99mTc-aprotinin: a new tracer for kidney morphology and function. Eur J Nucl Med 1984;9:257-260.
51. O'Connor CJ, Brown DV, Avramov M et al. The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass. Anesth Analg 1999;89:1101-1107.
52. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-1018.
53. Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999;89:57-64.
54. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-1291.
55. Anderson BJ, Meakin GH. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatric Anaesthesia 2002;12:205-219.
56. D'Errico CC, Shayevitz JR, Martindale SJ, Mosca RS, Bove EL. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996;83:1193-1199.
57. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997;113:194-201.
58. Linden MD, Schneider M, Erber WN. Factor V(LEIDEN) and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model. Perfusion 2001;16:476-484.